| FRANCE | WP5 | |||
| Organization | INSERM-APHP | |||
| Name of cohort | CoV-CONTACT | |||
| Referring partner | AP-HP | |||
| Cohort Information | Country(-ies), cities, regions or centers involved | France | ||
| Time of data collection | 03/2020 | 01/2023 | ||
| Enrolment | Inactive | |||
| Study setting | Multi-centers | |||
| Population | Age | Adults | ||
| Type | Prospective | |||
| Total number of patients | 317 | |||
| Data collection | Clinical data | True | ||
| Serological data | True | |||
| Genetic data | False | |||
| Sample collection | True | |||
| Sample collected | Whole blood | Yes | ||
| PBMC | No | |||
| Dry-spot blood | No | |||
| Plasma | No | |||
| Serum | No | |||
| Stool | No | |||
| NP swabs | Yes | |||
| Other | None | |||
| Description | Cov-CONTACT is a prospective cohort in HCWs who had a high-risk exposure to SARS-CoV-2-infected subject without personal protective equipment. Daily symptoms are self-reported for 30 days, nasopharyngeal swabs for SARS-CoV-2 RT-PCR are performed at inclusion and at days 3, 5, 7 and 12, SARS-CoV-2 serology is assessed at inclusion and at day 30. Confirmed infection is defined by positive RT-PCR or seroconversion, and possible infection by one general and one specific symptom for two consecutive days. | |||